COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
复制标题
COVID-19疫苗对Omicron（BA.2）变体的疫苗有效性。
DOI：
10.1016/s1473-3099(22)00309-7
复制
发表时间：
2022-07
影响因子：
56.3
通讯作者：
Bernal, Jamie Lopez
中科院分区：
文献类型：
--
作者：
Kirsebom, Freja C. M.;Andrews, Nick;Stowe, Julia;Toffa, Samuel;Sachdeva, Ruchira;Gallagher, Eileen;Groves, Natalie;O'Connell, Anne-Marie;Chand, Meera;Ramsay, Mary;Bernal, Jamie Lopez
Omicron（B. 1.1. 529)2021年11月27日在英国首次发现的变异株迅速成为主导菌株，部分原因是疫苗有效性降低。1 omicron亚谱系BA的测序病例增加。在2022年1月3日开始的一周内观察到2。2 BA。2的生长优势大于BA。13，4，并已成为英国的主导菌株在撰写本文时。使用单克隆抗体的中和试验表明BA之间存在小的抗原差异。1，BA。2，尽管来自加强疫苗接种个体的血清类似地中和了两种变体。3英国COVID-19疫苗接种计划自2020年12月8日起实施，主要疗程为两剂BNT 162 b2（Comirnaty，Pfizer-BioNTech）、ChAdOx 1-S（Vaxzevria，Oxford/AstraZeneca）或mRNA-1273（Spikevax，Moderna）。2021年9月14日，向50岁以上的成年人和风险人群引入了BNT 162 b2或半剂量（50 μg）mRNA-1273的加强疫苗接种，并于2021年11月29日向所有成年人引入。在这篇评论中，我们估计了疫苗对有症状疾病和BA住院治疗的有效性。1，BA。在共循环期间，在BNT 162 b2、ChAdOx 1-S或mRNA-1273的一个或两个剂量之后，以及在BNT 162 b2或mRNA-1273的加强剂量之后，我们采用了测试阴性病例对照研究设计。5-8我们的分析包括英国使用的所有疫苗。将疫苗接种状态作为自变量纳入，有效性定义为1减去病例中的疫苗接种几率，除以对照中的疫苗接种几率（附录第1-3页）。在2022年1月17日至3月31日期间，有1 127 517名有症状的个人进行了合格的测试，其中265 820人对BA呈阳性。BA阳性1246069例。2、615628例为阴性（对照组）。住院分析包括15043项合格检测，其中1662项为BA阳性。BA阳性1623例。2和12758为对照组（附录第4-7页）。
The omicron (B. 1.1. 529) variant, first detected in the UK on Nov 27, 2021, rapidly became the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in sequenced cases of the omicron sub-lineage BA. 2 was observed in the week beginning on Jan 3, 2022. 2 BA. 2 has a growth advantage over BA. 13, 4 and has become the dominant strain in the UK at the time of writing. Neutralisation assays using monoclonal antibodies have suggested a small antigenic difference between BA. 1 and BA. 2, although sera from individuals with booster vaccinations neutralise both variants similarly. 3 The UK COVID-19 vaccination programme has been in place since Dec 8, 2020, with primary courses of two doses of either BNT162b2 (Comirnaty, Pfizer–BioNTech), ChAdOx1-S (Vaxzevria, Oxford/AstraZeneca), or mRNA-1273 (Spikevax, Moderna). Booster vaccination with either BNT162b2 or a half dose (50 µg) of mRNA-1273 was introduced on Sept 14, 2021, to adults older than 50 years and those in risk groups, and on Nov 29, 2021, to all adults. In this Comment, we estimate vaccine effectiveness against symptomatic disease and hospitalisation with BA. 1 and BA. 2 after one or two doses of BNT162b2, ChAdOx1-S, or mRNA-1273, and after booster doses of BNT162b2 or mRNA-1273 during a period of cocirculation. We used a test-negative case-control study design. 5–8 Our analysis included all vaccines used in the UK. Vaccination status was included as an independent variable and effectiveness defined as 1 minus the odds of vaccination in cases, divided by the odds of vaccination in controls (appendix pp 1–3). Between Jan 17 and March 31, 2022, there were 1 127 517 eligible tests from symptomatic individuals, of which 265 820 were positive for BA. 1, 246 069 were positive for BA. 2, and 615 628 were negative (controls). The hospitalisation analysis included 15 043 eligible tests, of which 1662 were positive for BA. 1, 623 were positive for BA. 2, and 12 758 were controls (appendix pp 4–7).